Rivals Sun Pharma and Cipla beat third-quarter profit estimates, while Dr Reddy's missed expectations. All three drugmakers ...

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North ...

Indian drugmaker Alembic Pharmaceuticals reported a lower third-quarter profit on Monday, weighed down by weak local sales of its drugs that treat acute illnesses.

Tata Consumer Products expands food services and pharmacy channels nationwide, leveraging strong product portfolio post ...

Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Generic injectables maker Gland Pharma on February 3 reported a 7% rise in third-quarter profit, as lower expenses helped ...

Indian generic injectables maker Gland Pharma reported a 7% rise in third-quarter profit on Monday, as lower expenses helped mitigate the impact from production issues at its French unit ...

In the corresponding quarter of the previous fiscal, Alembic Pharmaceuticals posted a net profit of ₹180.4 crore. The company ...

Next week’s notable names in Q3 results include Tata Power, Swiggy, Bharti Airtel, Cochin Shipyard, Hero MotoCrop, Sula ...

Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...

Here’s a list of buy/sell recommendations for today from analysts: Raja Venkatraman, Ankush Bajaj, and MarketSmith India.

Earlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 ...